Compare · INGN vs SNN
INGN vs SNN
Side-by-side comparison of Inogen Inc (INGN) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGN and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.18B, about 72.9x INGN ($167.1M).
- SNN has been more active in the news (11 items in the past 4 weeks vs 3 for INGN).
- SNN has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Inogen Inc
- Smith & Nephew SNATS Inc.
- Price
- -
- -
- Market cap
- $167.1M
- $12.18B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 3
- 11
- Recent ratings
- 11
- 25
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest INGN
- Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
- Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
- SEC Form 4 filed by Inogen Inc
- EVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,500 shares, converted options into 18,136 shares and covered exercise/tax liability with 8,671 shares, increasing direct ownership by 50% to 32,972 units (SEC Form 4) (for tax liability)
- CEO and President Smith Kevin Raymond Merrill was granted 1,500 shares, increasing direct ownership by 1% to 134,962 units (SEC Form 4)
- SEC Form 10-Q filed by Inogen Inc
- Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inogen Announces Second Quarter 2026 Financial Results
- Smartbird Nominates Tech Industry Veterans Elizabeth Mora and Dan Kasun for Election to Its Board of Directors
Latest SNN
- SEC Form S-8 filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
- Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
- Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System